<DOC>
	<DOCNO>NCT00526279</DOCNO>
	<brief_summary>To evaluate compliance patient ' satisfaction mono combination treatment Candesartan cilexetil ( Atacand ) / Candesartan cilexetil 16mg , hydrochlorothiazide 12.5mg ( Atacand plus ) hypertension .</brief_summary>
	<brief_title>COmpliance Efficacy Mono Combination Tablet Study ATacand/Atacand Plus</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<criteria>1 . Patients consent participation/data release study 2 . Patients diagnosed hypertension prescribe atacand/atacand plus physician base clinical decision 1 . Secondary hypertension require therapy antihypertensive medication 2 . Patients prescribed atacand/atacand plus base safety reason reason determine physician 3 . Women pregnancy lactation 4 . Patients enrol study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Atacand/Atacand plus</keyword>
	<keyword>COMBAT</keyword>
	<keyword>Compliance</keyword>
	<keyword>Naturalistic</keyword>
	<keyword>Observational</keyword>
</DOC>